CytoDyn (CYDY)
(Delayed Data from OTC)
$0.26 USD
0.00 (-1.72%)
Updated Aug 8, 2025 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CYDY 0.26 0.00(-1.72%)
Will CYDY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CYDY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYDY
AutoNation Stock Falls 3.7% Since Q3 Earnings Miss Estimates
Penske Q3 Earnings Miss Expectations, Revenues Rise Y/Y
CYDY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lear Shares Shrink 4% Since Q3 Earnings Beat Expectations
Other News for CYDY
CytoDyn files $100M mixed securities shelf
CytoDyn (CYDY) Files for $100 Million Securities Offering
CytoDyn (CYDY) Files $100 Million Mixed Securities Shelf Offering
CytoDyn files $100M mixed securities shelf
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer ...